Details for Patent: 10,899,742

Which drugs does patent 10,899,742 protect, and when does it expire?

Patent 10,899,742 protects VEPPANU and is included in one NDA.

This patent has fifty-four patent family members in twenty-three countries.

Summary for Patent: 10,899,742

Title:	Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
Abstract:	The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
Inventor(s):	Andrew P. Crew, Yimin Qian, Hanqing Dong, Jing Wang
Assignee:	Arvinas Operations Inc
Application Number:	US16/744,414
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,899,742

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Arvinas Operations	VEPPANU	vepdegestrant	TABLET;ORAL	219835-001	May 1, 2026		RX	Yes	No	10,899,742					TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Arvinas Operations	VEPPANU	vepdegestrant	TABLET;ORAL	219835-002	May 1, 2026		RX	Yes	Yes	10,899,742					TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY

International Family Members for US Patent 10,899,742

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017366693
Australia	2020201793
Australia	2021204549
Australia	2021257895
Australia	2024201437
Australia	2026204234